Recurrent respiratory papillomatosis of the larynx : Gardasil® vaccination скачать в хорошем качестве

Recurrent respiratory papillomatosis of the larynx : Gardasil® vaccination

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,[email protected], https://plus.google.com/communities/1... , ,https://plus.google.com/u/0/+Alexandr... ,    / @otolaryngologistorlent-med3259   ,    / @alexandrosg.sfakianakis4746   , https://twitter.com/g_orl?lang=el,   / alexandrossfakianakis  , A retrospective case control analysis of the efficacy of Gardasil® vaccination in 28 patients with recurrent respiratory papillomatosis of the larynx. Clin Otolaryngol. 2018 Jan 30;: Authors: Milner TD, Harrison A, Montgomery J, MacGregor FB, Buchanan MA, MacKenzie K Abstract Recurrent respiratory papillomatosis (RRP) of the larynx represents a significant disease burden to patients and the healthcare system The use of HPV 6/11/16/18 vaccination (Gardasil® ) has previously been thought to impact on disease burden in patients with RRP. Gardasil® vaccination did not impact on the number of endolaryngeal surgical procedures required, the interval between procedures, or the number of patients who achieved disease remission in comparison to a control cohort. This study indicates Gardasil® vaccination does not appear to have any effect on disease burden in patients with RRP. The use of a control cohort profiles the natural progression of RRP. This article is protected by copyright. All rights reserved. PMID: 29380936 - video upload powered by https://www.TunesToTube.com